New Investor as of July 2013, but small biotech Investor.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m not knocking the graph per se, but I agree with your point.
Well, typically with a lower P-value, the higher the confidence, so I was confused as to why the P-Value got better as the number of deaths w/Lero went down, and vice versa.
Yeah, dude! Sorry. That reply was not for you specifically.
“The market”... this is the investment world’s fantasy definition of the matrix. The market is but one aspect of the whole investment scheme. In biotech, such as with Cytodyn, it is the product you bring to market as well. As long as Cytodyn can find investment money, the long term outlook looks bright. Being so close to data and approval, I doubt any major investors are going to allow this nest egg to drop and break.
See you in December!
Tis true.
Touche, friend. For sure this should have been approved sooner. No doubt about that.
It would be hard pressed for the fda to NOT approve Leronlimab for Covid before HIV. Why would they purposely sit on this drug when no other valuable candidates are close to data and demonstrated efficacy, as well as safety, like Leronlimab. It would defy logic.
Nice analysis. I’m confused, and maybe because it has been a while in statistics... why do you have a p-value getting greater after the number of Leronlimab deaths are going down? Should the p-value more likely get lower as the deaths are fewer?
Well, another article detailing how a Covid vaccine is unlikely to knock back the pandemic in any meaningful way in the short term. Something I and many others already knew.
https://www.google.com/amp/s/www.buzzfeednews.com/amphtml/danvergano/warp-speed-coronavirus-vaccines
Exactly. The Leronlimab egg is about crack open and reveal all the power behind its MOA. Any would be investors have a narrow window to jump in before Results are released and then it will be people trying to catch up to the train.
No sir. I was not saying that I believed the financials weren’t pretty. I was merely quoting you. Sorry that wasn’t clear. Seems the fda, montefiore, UCLA, and countless doctors disagree with a ‘snake oil’ designation. It seems the science contradicts that depiction. This is why Cytodyn is poised to succeed... other companies want in before results hit and the negotiations gets more expensive. Ah, if only the science could be argued as false... too bad it can’t! Lol!
Unfortunately, there is no proof that just because the financials aren’t pretty, that they are selling ‘snake oil’. This is an unfounded claim with Leronlimab specifically unless there is actual DATA that explicitly demonstrates otherwise.
Lol!
If all pans out the way we think it will, oh yeah they will be!
This is why Nader was so excited on the last live update. You could almost hear it in his voice how excited about the data that is coming. You don’t stop a trial early, Submit to publish more Articles, and choose to unblind data early unless you have VERY good news. On top of that, submit for up-listing....
Things will get very interesting by July, IMO.
Could be just coincidence, but I’ve noticed movement among Gilead in the Anti-inflammatory space (New Medical Director, I believe), and now Nash and arthritis chief from Stanford.
Me thinks they are understanding the wave coming from Cytodyn’s applications with Leronlimab. The race is on!
You’re going to compare Gilead, whose stock price is $75 per share, to Cytodyn, who is roughly $3 per share? Gilead is also on a major exchange and is also not a pre-revenue biotech. You’re comparing apples to oranges at the moment, with absolutely zero comment on the science.
See you in December!
You didn’t answer my question.
What part of the science is faulty?
At what time can emerging biotechs be considered not a scam when they are all starting out? Do only spin offs from major exchange biotechs only have credibility? Think of how many new drugs and lives lost that likely happened with that idea!
One positive is that little girl knowing how hard he fought for her mother. What an example of love for her to have!
Grip. Thank you for posting this. This is crushing news. Her husband had been such a champion for her cause. It’s a shame that the delay in her ability to receive treatment could have been prevented.
“Questions loom”...
Like what? Does it work in penguins in Antarctica?
Why would there be a need for a RS? The share price meets the requirement, and Cytodyn meets all the other requirements to uplist to at least the Nasdaq. There is no factual rationale for the idea that they would uplist to the OTCQX, let alone RS.
Boy,... that’s a whole lot of something to end up doing a whole lot of nothing.
That’s funny. The market closed green today.
By the way, Longs have about 50million reasons to be long right now. Lol. See you in December!
Totally agree. Even interim on 50 should be impressive, in my opinion.
So no names. Which is funny when you bolded “shareholders”. Unless there is an actual suit, there are no shareholders suing
Class action.... like all 100 companies such ‘law firms’ are investigating?
“Possibility”
Yep. Looks like the hope is on your end, not the Long’s. lMAO!
Lol! Lawsuits by shareholders? Any shareholders named? LMAO! Links?
Every drug company need fda approval. That isn’t a negative because it’s an even that hasn’t happened yet. They’ve only just applied for BLA. If the BLA were to get rejected, THAT would be a negative. But the company is progressing right along in terms of seeking approval. There is no negative that can reasonably been drawn from that as every company big or small has to apply to the fda and seek approval. Approval right now is a moot discussion at the moment.
It’s almost like saying the world is going to end because tomorrow hasn’t come yet.
Exactly, Black Ops.
Funny all the criticism over share price and valuation with no figures or projection of any kind. But this is what I find most humorous. Many who paint a negative scenario would likely ask for Leronlimab for the conditions they are currently treating. Safe and effective? I don’t know of any patient dumb enough to refuse such a drug. That means Cytodyn’s moment to shine is all just a matter of time and data.
I think others have said this before “pre revenue”.....like a lot of pre revenue biotechs on the otc. Up list and data. See you in December. Scientific data is not Hope. Those are real numbers, real patients, and a real MOA. This is an underdog story of epic proportions, and current share price is a minor detail in whole scheme of things. Hope. That’s kind of an ironic word, you think?
Why is this bad for Cytodyn? Leronlimab is not a vaccine. It for people infected who are in the midst of potential it cytokine storm. Fail to see your point. It’s almost as if all those deaths in New York are being denied ever happened. Smh.
Lol! A realist who cannot come up with any valuation projections of his own. How do you think Cytodyn got to this point to begin with? Sure ain’t dreams!
I don’t agree either. It may be after hours, but why list so many indications? Especially Nash, GvHD and MS?
Totally agree with your sentiment. Nader is moving quickly. This company is leaving the train station and it’s leaving at the pace of a bullet train, not a steam loco.
Awesome find, Jenny! Thanks for the link and Due Diligence. There are only a handful of members that actually NEED it. Lol. For the rest, it is great information and affirmation of what is a great drug! Welcome to the board!
Thanks ombowstring!
Molecular Formula: C6534 H10036 N1720 O2040 S42
Lol! Yep! Sooooo easy! LMAO! If you’re a chemist, good luck! If not, you’re making claims you cannot prove. Good luck trying to make a ‘biosimilar’ that does the same thing with the exact same safety profile! LMAO!
Who cares! No one has been able to reproduce it, patents are in process, and patents already cover the myriad of conditions they are aiming for. Like I said, having a parent for the drug NOW improves its protection at such a pivot moment in the company’s timeline. This is a moot discussion. LMAO!
LMAO! There’s a huge difference between the raw materials for manufacturing, and the manufacturing process itself. Bold and underline do nothing to explain this. LMAO!
I have pennies in my pocket and rubber in my shoe soles, but that doesn’t mean I magically have copper wire! LMAO!